Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage biopharmaceutical company that develops and commercializes treatments for immune-mediated dermatological diseases. Its marketed portfolio centers on ZORYVE (roflumilast), a once-daily topical PDE4 inhibitor available as creams and foam for plaque… From the company’s description.
Over the twelve months to Sep 30, 2026, Arcutis Biotherapeutics, Inc. reported revenue of $508.68M, up 60.0% from a year earlier, and net income of $29.91M. Its operating margin was 6.9%, and operations generated $59.96M in cash. In fiscal 2025, it reported revenue of $376.07M, up 91.3% from fiscal 2024, and a net loss of $16.14M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arcutis Biotherapeutics, Inc. does
In the company’s own words
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage biopharmaceutical company that develops and commercializes treatments for immune-mediated dermatological diseases. Its marketed portfolio centers on ZORYVE (roflumilast), a once-daily topical PDE4 inhibitor available as creams and foam for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The products are approved for adults and, depending on formulation and indication, children; they are marketed in the United States and Canada. Arcutis also develops ZORYVE for additional indications, including hidradenitis suppurativa and vitiligo, and is advancing ARQ-234, a CD200 receptor agonist fusion protein, as a potential treatment for atopic dermatitis and other inflammatory conditions. The company licensed worldwide dermatological rights to topical roflumilast from AstraZeneca in 2018 and acquired Ducentis BioTherapeutics, including ARQ-234, in 2022. It has licensing collaborations for topical roflumilast in Greater China and Southeast Asia and in Japan. Its website is https://www.arcutis.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WESTLAKE VILLAGE, CA
- Fiscal year end
- December
- CIK
- 1787306
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arcutis Biotherapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arcutis Biotherapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arcutis Biotherapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arcutis Biotherapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arcutis Biotherapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”